Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 62M | 59M | 72M | 87M | 67M |
| Gross Profit | 22M | 24M | 32M | 38M | 31M |
| Operating Income | 1M | 5M | 12M | 15M | 12M |
| EBITDA | 11M | 13M | 19M | 23M | 19M |
| Net Income | 2M | 4M | 9M | 11M | 9M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$24.00
+0.00% today
Window Change
+0.00%
Window
Jun 23, 2025 → Mar 30, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 194 bars · Jun 23, 2025 → Mar 30, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Probi AB (publ) (PBBIF) is a Healthcare stock with a market cap of $286.93M and listed on OTC. The stock last traded around $24.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Mar 30, 2026). Baseline metrics include revenue growth of +4.9%, EPS growth of -55.9%, a dividend yield of 0.0%. What stands out right now is revenue +4.9%, EPS -55.9%, free cash flow -57.5% with operating margin 1.8% and ROIC 0.8%. Valuation already assumes a fairly strong business story at P/E 235.8 and price/sales 6.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PBBIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PBBIF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PBBIF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PBBIF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$66.9M
-23.4% YoY
FY Net Income
$9.2M
-18.7% YoY
Free Cash Flow
$14.6M
+24.0% YoY
Revenue Growth
+4.9%
EPS Growth
-55.9%
Gross Margin
35.1%
Net Margin
2.7%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 62M | 59M | 72M | 87M | 67M |
| Gross Profit | 22M | 24M | 32M | 38M | 31M |
| Operating Income | 1M | 5M | 12M | 15M | 12M |
| EBITDA | 11M | 13M | 19M | 23M | 19M |
| Net Income | 2M | 4M | 9M | 11M | 9M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33M | 31M | 28M | 26M | 22M |
| Total Assets | 153M | 154M | 166M | 158M | 138M |
| Total Liabilities | 18M | 20M | 26M | 22M | 15M |
| Shareholder Equity | 135M | 135M | 139M | 136M | 123M |
| Total Debt | 6M | 7M | 9M | 6M | 7M |
| Net Debt | -27M | -23M | -19M | -20M | -16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
18M
+7.6% YoY
Capital Expenditures
4M
+28.9% YoY
Free Cash Flow
15M
+24.0% YoY
Key ratios
Gross Margin
35.1%
Operating Margin
1.8%
Net Margin
2.7%
ROE
1.2%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.